These quotes are a couple years old now (taken from an old Henslow report when they were lead broker) but are still valuable to consider with respect to the unique nature of the IP we have (new mode of action). This is a very niche stock with little to compare to you have to go back to 2008 to get a decent comparable. A true needle in the haystack with global potential. Momentum is now with us as lots of testing has been done internally and externally with stakeholders, checking key boxes for toxicity along the path to registration with the relevant bodies (such as IRAC) around the world, the need for our product is greater than ever.
"The insecticide market has a total value of +US$31.1bn, with resistance to remaining insecticidal compounds growing. The Chemical industry is desperately seeking new compounds to combat this issue."
"Each chemical class identified by IRAC attack pests in different ways (Novel Modes of Action). Beta-Triketones have shown evidence of targeting a unique site, which is subject to proprietary confidentiality, but appear to interfere with the Nerve & Muscle system of pests. The discovery of Beta-Triketones as compounds capable of being used as insecticides is effectively a 1 in +140,000 chance, what we understand as being the scientific equivalent of finding a needle in a haystack. Additional MoA’s being discovered and introduced into rotation do not present a competitive threat to BGT’s compound, but a mechanism that extends the longevity of all MoA’s, curtailing resistance."
"BGT will replicate the success of Nihon’s platform technology developed for the diamides insecticide class. Novel MoA’s being used in scale is extremely rare, the last being commercialised in 2008 by Japanese Company Nihon Nohyaku: Diamides (Novel 28). By 2013 (5-years after first use) Diamides recorded global sales of +US$1.4bn, which it has maintained annually, hence once discovered Novel MoA’s have the potential to be extremely valuable."
